Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02594124 · ClinicalTrials.gov registry record · Phase 3
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
NCT02594124 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 292 participants.
The verdict
NCT02594124, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
Study Summary
The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. The secondary objective is to examine the long-term efficacy of nusinersen administered by IT injection to participants with SMA who previously participated in investigational studies of nusinersen.
Interventions
- DRUG nusinersen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2023-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02594124
The ClinicalTrials.gov registry entry for NCT02594124 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nusinersen is the first listed.
NCT02594124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02594124 about?
NCT02594124 is a clinical study titled "A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies". The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. The secondary objective is to examine...
What is the current status of trial NCT02594124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2015-11-04. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT02594124?
The interventions under investigation include: nusinersen (DRUG).
Who is sponsoring clinical trial NCT02594124?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.